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Abstract
Purpose. Original articles and abstracts published between January 1991 and January 1997 were selected according to
specified criteria and reviewed to provide answers to five interesting questions about the systemic treatment of metastatic
osteosarcoma.
Results.
(1) In patients with metastatic disease at presentation, what is the outcome after intensive multi-agent chemotherapy?
Historically, survival has been poor, but may be improving with the use of ifosfamide-containing regimens.
(2) Can response to new agents be evaluated better in patients who have received no previous chemotherapy?
Based on limited data, this is probably true.
(3) Is the response to neo-adjuvant chemotherapy, as determined by histopathology, similar for the primary tumor and
synchronous pulmonary metastases?
With intensive multi-agent chemotherapy, good histological response rates are in the range 70-90% for both groups.
(4) What is the outcome, after intensive combined modality treatment with chemotherapy and surgery, in patients
relapsing with metastases after previous adjuvant chemotherapy, and what are the important prognostic factors?
Outcome is highly variable, but 5-year survival ranges between 25 and 50% and a good outcome is more likely if
recurrent disease is limited to resectable lung metastases.
(5) Can a biological agent (L-MTP-PE) prolong the time to relapse in patients with resected metastatic osteosarcoma?
Preliminary data suggest that this is possible, but more studies are required.
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Introduction
With modem intensive multi-agent chemotherapy,
5-year overall survival (OS) figures for non-
metastatic extremity osteosarcoma of children and
young adults have improved and are in the range
40-80%. Unfortunately, between 15 and 20% of
patients with osteosarcoma will present with clini-
cally detectable metastases, a proportion that has
increased with sophisticated methods of detection
such as computed tomography (CT) or magnetic
resonance imaging (MRI). As determined by
measurable clinical response, chemotherapy so far
has produced rather unimpressive results in
metastatic osteosarcoma.2 Early data showed overall
response rates for single agents such as doxorubicin
(DOX), cisplatinum (DDP), high-dose methotrex-
ate (HDMTX) and ifosfamide (IFOS) of between
15 and 25%, with even lower response rates, 8-
15/% for agents such as bleomycin, cyclophos-
phamide, actinomycin D (BCD), dacarbazine,
melphalan and mitomycin C.
The serendipitous discovery that high rates of
necrosis could occur in tumors of patients receiving
neo-adjuvant chemotherapy while awaiting manu-
facture of prostheses,
3 and the establishment of a
clear link between a good pathological response
(> 90% necrosis) in the primary and a good out-
come, have significantly changed the approach to
the management of osteosarcoma. Although the
most dramatic results have been achieved in non-
metastatic cases, some promising advances in
metastatic disease (regimens incorporating IFOS,
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biological therapy) that have provided interesting
strategies for early stage disease are reviewed here.
Methods
The scope of this review is limited to articles pub-
lished between January 1991 and January 1997.
Previous reviews in 19872 and 19951 by the same
author covered much of the earlier literature.
Data identification
A computerized search of Medline and Cancerlit
databases for the years January 1991-January 1997
was performed specifying the key words ’osteosar-
coma’ and ’chemotherapy’, and limiting the search
to the English language. This was supplemented by
papers in the author’s files and scrutiny of reference
lists of previous reviews and key articles.
Data selection
Publications were selected for review if they met the
following criteria:
(1) patients had histologically confirmed osteosar-
coma;
(2) metastases were present at diagnosis, or devel-
oped subsequently;
(3) patients received some form of systemic
treatment;
(4) minimum of 11 evaluable patients were avail-
able for analysis;
(5) if survival was a principal outcome, minimum
follow-up of 12 months or median of > 24
months.
Review articles were excluded. Reports of single
institutional experience with multiple chemotherapy
regimens were excluded, unless these focused on
prognostic factor analyses. If several papers con-
tained similar data the most recent and/or most
informative paper was included. The reviewed stud-
ies have been organized around a series of questions
for which the results have relevance. However, this
grouping may not always reflect the primary purpose
of the study.
In the studies selected, the majority of patients
were children/young adults with common, high-
grade osteosarcoma. Data on histological response
in text and tables are referred to as ’good’ and ’poor’
corresponding to > 90% necrosis and < 90%
necrosis, respectively.
Results and discussion
(1) In patients with metastatic disease at presen-
tation, what is the outcome after intensive
multi-agent chemotherapy?
Five studies are detailed in Table 1. The two largest
studies with the longest follow-up4’ show that the
outlook is poor: 18% OS at a median follow-up of
84 months and 11% OS at a minimum follow-up of
60 months. In the study from Memphis
6 the
Kaplan-Meier curve indicates an OS of approxi-
mately 30% at 60 months but this study only
included patients with pulmonary metastases. All of
these patients had persistent disease and many
would have eventually succumbed. Similarly, in the
first Bologna study reporting on patients treated
between 1986 and 19907 the disease-free survival
(DFS) figure at 30 months of 26% suggests a poor
long-term prognosis. The presence of bone metas-
tases at presentation was an adverse prognostic fac-
tor4’5 as all patients in both studies died. In a
multivariate analysis, Meyers et al. found that a
better outcome was also associated with age over 21
years, response to pre-operative chemotherapy and
completeness of resection at all sites of tumor. Sur-
vival was not affected by use of pre-operative
chemotherapy vs immediate surgery, and did not
correlate with levels of lactic dehydrogenase, alka-
line phosphatase or the site of primary tumor.
Two more recent studies have produced relatively
encouraging results, although follow-up is shorter.
The 5-year relapse-free survival (RFS) figure of42%
(Table 2) for a series of 33 patients treated on a
Pediatric Oncology Group (POG) ’therapeutic win-
dow’ study (see next section) is promising. 8’9 Simi-
larly, in a second study
1 of 23 patients treated in
Bologna between 1993 and 1995 (Table 1) the
projected 2-year survival was 45% (mean follow-up
24 months) and 10 patients were continuously dis-
ease-free at the time of reporting. Both these studies
incorporated IFOS into intensive multi-agent regi-
mens of HDMTX/DDP/DOX.
(2) Can response to new agents be evaluated better
in patients who have received no previous
chemotherapy?
Evaluating new agents in patients with poor prog-
nosis (usually due to the presence of metastatic
disease at presentation) by giving two courses of a
new agent before surgery, to be followed by inten-
sive multi-agent chemotherapy, has been referred to
as ’therapeutic window’ treatment (Table 2). The
postulate that the activity ofnew drugs can better be
evaluated in tumors not previously exposed to
chemotherapy seems to be confirmed by the results
of a POG study reported by Harris et al.
9 For
single-agent IFOS, a response rate of 27% was
observed in 33 patients treated by this method, in
contrast with 10% in a non-randomized group of 30
patients relapsing after intensive multi-agent chemo-
therapy (p 0.04). In a second study of carboplatin
(CARBO), Ferguson et al. 11 using a mixture of
clinical, radiological and pathological response cri-
teria showed that only 1/34 (3%) patients had a




zsidered, but 8/34 patients showed a response at one
or more individual sites. This was felt to be lower
than might be expected for DDP.
In contrast, several groups have shown low or
negligible response rates when evaluating single
agents in patients relapsing after multi-agent chemo-
therapy. As shown in Table 2, CARBO was inac-
tive,
12 as was paclitaxe113 and oral etoposide.
14
Pappo et al.
15 retrospectively evaluated the response
to salvage chemotherapy in 86 patients with recur-
rent or metastatic disease after at least one treat-
ment regimen comprising chemotherapy and/or
surgery. One to six post-relapse single- or multi-
agent treatments were delivered. Responses were
not seen from regimen 3 onwards and response rates
were 13% and 7% for regimens 1 and 2, respect-
ively. Responses were seen only with HDMTX (2/
25 patients), DDP (3/18 patients), IFOS (8/20
patients) and etoposide (VP-16)/CARBO (1/1
patient).
The French Society of Pediatric Oncology
(SFOP) achieved better results, with a 48% clinical
response rate (2 good pathological responses) in
25 patients receiving combination chemotherapy
(IFOS/VP-16) at relapse after adjuvant HDMTX/
DON.
16
(3) Is the response to neo-adjuvant chemotherapy,
as determined by histopathology, similar for the
primary tumor and synchronous pulmonary
metastases?
Biagini et al.
7 were able to compare histological
response between the primary tumor and metastases
in all 23 patients in the first Bologna study. Overall,
71 metastatic nodules were removed and a good
response was observed in 17 (24%) of these. In six
patients showing a good response in the primary
tumor, the response was also good in 12/21 (57%)
metastases. Conversely, in 17 patients showing poor
response in the primary only 5/50 (10%) metastases
showed a good response. The rate of good response
in the primary tumor was lower (26%) in this series
of patients presenting with metastatic disease than
in 168 patients with localized disease receiving simi-
lar chemotherapy (76%).
However, in a second Bologna study,1 a good
response was observed in a higher proportion of
metastatic lesions, 71/79 (89%). This was also true
for the primary tumors with 11/15 (73%) respond-
ing. Although there was no significant difference in
the proportion of good responses between
metastatic and primary tumors, the incidence of
complete necrosis was significantly better
(p 0.0061) in metastatic vs primary tumors, 52/79
(66%) vs 3/15 (20%). In 13 patients showing a good
response of the primary tumor, 11 (85%) showed a
good response in all their metastases. Conversely, of
five patients with a poor histological response in the
primary, two had a good response in metastases,
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two a poor response and there was one mixed
response.
(4) What is the outcome, after intensive combined
modality treatment with chemotherapy and
surgery, in patients relapsing with metastases
after previous adjuvant chemotherapy, and what
are the important prognostic factors?
In Table 3, five studies17-21 show the results of
combined modality treatment with surgery and
chemotherapy for patients relapsing after adjuvant
treatment. Two studies19’ only report results in
patients with lung metastases: these studies are het-
erogeneous in terms of prior therapy, subsequent
treatments and outcomes reported. It is clear that
some patients can be salvaged by aggressive treat-
ment and the outlook may not be dissimilar to that
reported for patients presenting with lung metas-
tases (Table 2). In three of the four studies in which
a prognostic factor analysis was performed, com-
plete resection of metastases was independently cor-
related with improved survival.
In the multi-institutional study (MIOS), patients
relapsing after surgery alone had a significantly
longer interval to further disease progression
(p<0.01) and improved survival after relapse
(p- 0.01) compared with those relapsing after treat-
ment with immediate chemotherapy.
1
(5) Can a biological agent (L-MTP-PE) prolong
the time to relapse in patients with resected
metastatic osteosarcoma?
Kleinerman and co-workers have published a series
of studies on liposome-encapsulated muramyl
tripeptide-phosphatidyl ethanolamine (L-MTP-PE)
which has been shown to activate canine adherent
mononuclear cells to become cytotoxic against can-
ine osteosarcoma cells. This agent improved survival
in a randomized trial when it was given as adjuvant
therapy vs control in dogs undergoing amputation
for osteosarcoma. Preliminary in vitro studies
23
demonstrated that the tumoricidal properties of
monocytes from 25 patients with osteosarcoma
could be activated by L-MTP-PE to levels equal to,
or greater than, those expressed by normal mono-
cytes from control patients. Single-agent chemo-
therapy with DDP, DOX, HDMTX and
cyclophosphamide did not interfere with this acti-
vation process and there was even a suggestion of
enhanced activation potential following administra-
tion of DOX. In a subsequent study,
z4 specific bio-
logical effects were shown in patients receiving
infusions of L-MTP-PE, 2 mg m -z twice weekly
12, then weekly 12. These included rapid
induction of circulating tumor necrosis factor
(TNF) and interleukin-6 (IL-6) as well as more
prolonged elevations of C-reactive proteins and
neopterin. This study went on to accrue 28 patients
who had developed pulmonary metastases during
adjuvant chemotherapy, or who presented with pul-128 V. Bramwellmonary metastases that persisted despite chemo-
therapy. All patients were rendered free of visible
disease by surgery before administration ofL-MTP-
PE. In five patients, a single tumor nodule recurred
within 6 weeks of completing immunotherapy
25 and
was resected. In three cases, histology of the tumor
nodules showed peripheral fibrosis, an inflammatory
cell infiltrate and neovascularity; the fourth showed
early fibrosis and in the fifth the histology had
changed from high to low grade. The clinical out-
come was compared6 between 12 patients receiving
12 weeks of therapy (group 1) and 16 patients
receiving 24 weeks of therapy (group 2), as well as
a similar group of historical controls (1980-1990)
who received chemotherapy (group 3). There was a
significant difference in time to relapse between
groups 2 and 3 (9 vs 4.5 months). In nine patients,
administration of L-MTP-PE in combination with
IFOS 1.8 g m- day- 5 did not seem to increase
toxicity and was well tolerated.7 Immune activation
was similar to that observed for L-MTP-PE alone
and histological changes compatible with a chemo-
therapy effect (necrosis) and an immune effect
(fibrosis with inflammatory cell infiltrate) were seen
in three patients.
L-MTP-PE is currently (since November 1993)
being evaluated in an intergroup trial (CCG 7921;
POG 9351; INT 0133) in patients with non-
metastatic osteosarcoma. Patients first receive
induction chemotherapy with DOX/HDMTX with
or without IFOS. After definitive surgery, they
receive maintenance therapy with DOX/DDP/
HDMTX and/or IFOS and are randomized
between L-MTP-PE and control, given during and






Long-term survival in osteosarcoma patients
presenting with metastatic disease has been
poor historically, especially for those with
metastases in bone. Early results seem better for
intensive multi-agent combinations incorporat-
ing IFOS, but these must be confirmed by
long-term follow-up.
In a non-randomized study, IFOS showed
greater activity as a single agent in patients who
had not received previous chemotherapy than in
patients relapsing after prior chemotherapy.
Thus, the ’therapeutic window’ method may
provide a better assessment of the efficacy of a
new drug. CARBO showed low activity in pre-
viously untreated patients suggesting that it
should not replace DDP in potentially curative
regimens. Responses rarely occur in patients
who have received three or more regimens of
chemotherapy.
When IFOS is incorporated in intensive multi-




response rates are high (70-90%) in both pri-
mary tumors and pulmonary metastases. How-
ever, there may be technical variations in
assessing cell kill in bone and lung.
Based on 5-year survival figures, somewhere
between one-quarter to one-half of patients with
systemic relapse can be salvaged with intensive
multi-modality therapy. The outlook seems bet-
ter if metastatic disease can be completely
resected.
Studies have confirmed the immuno-stimula-
tory effects of L-MTP-PE and histopathologic
studies suggest an inflammatory/fibrotic effect
in lung metastases. A very small non random-
ized study has found extended DFS in patients
receiving L-MTP-PE after resection of lung
metastases, in comparison with historical con-
trois.
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